Articles by Gordon Brown, DO
Dr. Brown breaks down the CREST trial results in high-risk NMIBC, highlighting the benefits of combining sasanlimab with BCG.
Dr. Brown discusses the latest TAR-200 data from the SunRISe-1 trial in BCG-unresponsive NMIBC, highlighting CR rates.
The panel concludes with a discussion on how recent Medicare Part D reforms have capped patient out-of-pocket costs.
The panel transitions to role of bone-protecting agents, highlighting the importance of baseline DEXA scans.
The panel weighs some more nuanced decision-making for selecting among androgen receptor pathway inhibitors.
The panel delves into the nuanced decision-making around using doublet versus triplet systemic therapy in mHSPC.
The panel considers the challenges of applying trial data based on conventional imaging to today's PSMA PET-guided staging.
The panel explores the decision-making around offering RP to patients with borderline or undetected mHSPC on PSMA PET.
The panel discusses the role of PSMA PET imaging in staging and managing mHSPC, highlighting insurance barriers and more.
In the final segment of the roundtable, the panel debates the real-world integration of new therapies into everyday practice.
In part five of this NMIBC roundtable, the panelists discuss integrating new therapies such as TAR-200 into clinical practice
Part four of this roundtable series examines the SunRISe-1 trial results for high-risk NMIBC.
The panelists discuss advancements in NMIBC treatment in part three of this roundtable, including pembrolizumab and TAR-200.
Part two of this roundtable explores intravesical and systemic therapies, and the importance of accurate risk stratification.
The first part of this roundtable focuses on recent trial data, the role of TUR quality, and precision medicine for NMIBC.
Dr. Brown shares highlights from the CME program at LUPGA 2024, including new trends in bladder, kidney, and prostate cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.